AU784245B2 - Medicament in order to induce tolerance - Google Patents

Medicament in order to induce tolerance Download PDF

Info

Publication number
AU784245B2
AU784245B2 AU19972/01A AU1997201A AU784245B2 AU 784245 B2 AU784245 B2 AU 784245B2 AU 19972/01 A AU19972/01 A AU 19972/01A AU 1997201 A AU1997201 A AU 1997201A AU 784245 B2 AU784245 B2 AU 784245B2
Authority
AU
Australia
Prior art keywords
antigen
medicament
inhibitor
tolerance
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU19972/01A
Other languages
English (en)
Other versions
AU1997201A (en
Inventor
Thomas Wilckens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onepharm Research and Development GmbH
Original Assignee
BIONETWORKS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIONETWORKS GmbH filed Critical BIONETWORKS GmbH
Publication of AU1997201A publication Critical patent/AU1997201A/en
Application granted granted Critical
Publication of AU784245B2 publication Critical patent/AU784245B2/en
Assigned to ONEPHARM RESEARCH & DEVELOPMENT GMBH reassignment ONEPHARM RESEARCH & DEVELOPMENT GMBH Alteration of Name(s) in Register under S187 Assignors: BIONETWORKS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
AU19972/01A 1999-10-28 2000-10-27 Medicament in order to induce tolerance Ceased AU784245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19951970A DE19951970A1 (de) 1999-10-28 1999-10-28 Arzneimittel für die Toleranzinduktion
DE19951970 1999-10-28
PCT/EP2000/010594 WO2001030383A2 (de) 1999-10-28 2000-10-27 Arzneimittel für die toleranzinduktion

Publications (2)

Publication Number Publication Date
AU1997201A AU1997201A (en) 2001-05-08
AU784245B2 true AU784245B2 (en) 2006-02-23

Family

ID=7927188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19972/01A Ceased AU784245B2 (en) 1999-10-28 2000-10-27 Medicament in order to induce tolerance

Country Status (9)

Country Link
EP (1) EP1223974A2 (zh)
JP (1) JP2003512438A (zh)
KR (1) KR20020057986A (zh)
CN (1) CN1391479A (zh)
AU (1) AU784245B2 (zh)
CA (1) CA2388974A1 (zh)
DE (1) DE19951970A1 (zh)
NZ (1) NZ518567A (zh)
WO (1) WO2001030383A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
CA2516291C (en) * 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20100087413A1 (en) * 2003-09-22 2010-04-08 Thomas Wilckens Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CN107261154A (zh) 2011-04-29 2017-10-20 西莱克塔生物科技公司 致耐受性合成纳米载体
AU2014262163A1 (en) 2013-05-03 2015-11-19 Selecta Biosciences, Inc. Delivery of immunosuppressants having a specified pharmacodynamic effective-life and antigen for the inducation of immune tolerance
EP3189138A4 (en) 2014-09-07 2018-04-18 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
JP2019182845A (ja) * 2018-04-02 2019-10-24 学校法人藤田学園 キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
GB8824835D0 (en) * 1988-10-24 1988-11-30 Univ Court Of The University O Administrations of corticosteroids
EP0494224B1 (en) * 1989-09-25 2000-05-10 University Of Utah Research Foundation Use of steroid hormones in compositions for inducing t cell lymphokine production
JPH04243833A (ja) * 1991-01-28 1992-08-31 Tsumura & Co １１β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US5591771A (en) * 1991-12-17 1997-01-07 Michel Fockerman Use of propolis components as an adjuvant
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5883240A (en) * 1995-08-24 1999-03-16 Baker Medical Research Institute Genetic sequences encoding glucocorticoid dehydrogenases and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABSTRACT 8595068;BERTI F ET AL. OCT.'95,VOL.45(10) PG 1098 *
SEE ISR OF WO 2001/030383 *

Also Published As

Publication number Publication date
KR20020057986A (ko) 2002-07-12
NZ518567A (en) 2004-09-24
WO2001030383A2 (de) 2001-05-03
JP2003512438A (ja) 2003-04-02
WO2001030383A3 (de) 2001-11-08
EP1223974A2 (de) 2002-07-24
CA2388974A1 (en) 2001-05-03
DE19951970A1 (de) 2001-05-03
CN1391479A (zh) 2003-01-15
AU1997201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
AU784245B2 (en) Medicament in order to induce tolerance
AU2003219383B2 (en) Oligonucleotide compositions and their use for the modulation of immune responses
EP2842568B1 (en) Pharmaceutical composition for treating and/or preventing type i diabetes and application thereof
CA2160543C (en) Methods and compositions for delaying or preventing the onset of autoimmune disease
Dénes et al. Autoantigens plus interleukin-10 suppress diabetes autoimmunity
Ou et al. Intranasal immunization with DNA vaccine coexpressing Der p 1 and ubiquitin in an allergic rhinitis mouse model
WO2003096967A2 (en) Dna vaccines encoding heat shock proteins
AU3601499A (en) Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions
EP1536826B1 (en) Igf-2 peptide for use in tolerogenic approaches for type i diabetes.
Alexander et al. Peptide-based vaccines in the treatment of specific allergy
Dénes et al. Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses
Ferreira et al. Customized antigens for desensitizing allergic patients
WO2005084137A2 (en) Cd25 dna vaccines for treating and preventing t-cell mediated diseases
Biregani et al. Allergen specific immunotherapy with plasmid DNA encoding OVA-immunodominant T cell epitope fused to Tregitope in a murine model of allergy
AU2021267369A1 (en) Immunogenic peptides with extended oxidoreductase motifs
Liu et al. Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial
Verhagen et al. Advances in allergen-specific immunotherapy
Chan et al. Recombinant adenovirus encoding gp100 modulates experimental melanin-protein induced uveitis (EMIU)
Zou et al. Ethylenecarbodiimide-fixed splenocytes carrying whole islet antigens decrease the incidence of diabetes in NOD mice via down-regulation of effector memory T cells and autoantibodies
Soyer et al. Immunologic Responses to Sublingual Allergen Immunotherapy
JP2024523476A (ja) 自己免疫に対する新規ｍＲＮＡワクチン
Jie et al. Increased inhibitory surface marker PD-1 expression in CD4+ T cells and Th2+ T cells in allergen-specific immunotherapy
Caspi Immunotherapy of uveitis: is gene therapy in our future?
Dziadzio et al. New antiallergic drugs
Schwartz Immune-Based Cell Therapy for Acute and Chronic Neurodegeneratlve Disorders